Every session across each track delivered is backed by proven ROI - this is the real value in attending LEAP HR: Life Sciences East.
Over $100M in targeted cost savings over three years, delivered through an end-to-end R&D transformation across 2,500 employees in 35 countries in just 6–9 months.
CSL
Over $80M in cost avoidance over six years by eliminating reliance on retained search firms, while improving quality of hire, leadership readiness, and long-term retention.
Roche
Tens of millions of dollars in cost savings from centralizing L&D enterprise-wide, plus one set of leadership standards established across the business.
Merck & Co
TA annual operating costs reduced by approximately 50%, with millions redirected from low-impact programs to evidence-based interventions delivering measurably better talent outcomes.
Takeda
$4M in expense reduction through redesigned time-off policies, without compromising employee benefits or experience.
Sarah Cannon Research Institute
93%+ engagement, 100% employee advocacy, and zero regrettable turnover sustained through the first years of scaling.
Sionna Therapeutics
First-year culture transformation awareness scores above 4.2/5 across all regions, with measurable leadership accountability established.
Ferring Pharmaceuticals
Three INDs filed in one year, $413M raised (Series A) and $250M (Series B), and Great Place to Work® certification achieved — all built from zero people infrastructure.
Mirador
Seamless global reorganization impacting ~9,000 roles, improving spans of control, reducing duplication, and delivering a flatter, more agile organization with minimal business disruption.
Novo Nordisk
Manufacturing site scaled from start-up to nearly 600 employees, before evolving to support a population of over 2,000 — supported by a lean HRBP team.
BioMarin Pharmaceutical
Engagement scores retained above 90% and turnover below 5%, delivering higher fairness and greater cultural energy without expensive programs or large HR teams.
Grey Wolf Therapeutics
A 15-person HR team transformed into a single cohesive function, improving decision-making speed and reducing operational friction across a 550-employee organization over three years.
Arcus Biosciences
Scaled from fewer than 200 to 756+ employees globally in 4.5 years, enabling a full commercial build completed in one year.
Corcept Therapeutics
Reduced reliance on external hiring throughout a six-month talent-at-risk period during a prolonged acquisition, delivering exceptionally low regrettable attrition.
Blueprint Medicines
Sustained cross-level engagement over 18 months through the Stop the Swirl initiative, with measurable participation data and improved execution discipline across R&D.
Ultragenyx
Uplift across every culture survey question and a +7 point cumulative culture score increase post-RIF, demonstrating a direct link between values-led leadership and business readiness ahead of FDA approval.
Travere Therapeutics
Built two distinct sales forces and planned a 30–40% expansion of the US sales organization within a single year, through redesigned hiring for ambiguous, fast-evolving roles.
Alnylam Pharmaceuticals
Explore the Agenda to Discover the Translational to Access Priorities Shaping Dermatology R&D in 2026
Explore a focused agenda of scientific case studies, expert panels and interactive discussions designed to help you discover novel targets, improve translational confidence, optimize clinical development, differentiate therapies and accelerate the next generation of dermatology innovation across both common and rare inflammatory skin diseases.
Partner to Position Your Solutions at the Centre of Active Dermatology Pipelines
Partner with the summit to showcase your capabilities to senior pharma and biotech teams actively seeking support across biomarkers, imaging, clinical trials, manufacturing and formulation.
Join Biopharma Experts to Connect with the Decision-Makers Driving Dermatology Development Forward
Join a global audience of 90+ senior leaders from pharma and biotech for high-value networking, candid peer exchange and relationship-building across preclinical and late-stage development, access and launch.